Enveric Biosciences, Inc.
ENVB
$1.42
$0.09086.83%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -10.37% | -39.08% | |||
| Depreciation & Amortization | -50.62% | -1.82% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 15.15% | -31.08% | |||
| Operating Income | -15.15% | 31.08% | |||
| Income Before Tax | -15.30% | 30.58% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -15.30% | 30.74% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -15.30% | 30.74% | |||
| EBIT | -15.15% | 31.08% | |||
| EBITDA | -17.69% | 31.86% | |||
| EPS Basic | 20.15% | 74.67% | |||
| Normalized Basic EPS | 20.14% | 74.62% | |||
| EPS Diluted | 20.15% | 74.67% | |||
| Normalized Diluted EPS | 20.14% | 74.62% | |||
| Average Basic Shares Outstanding | 44.38% | 173.47% | |||
| Average Diluted Shares Outstanding | 44.38% | 173.47% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||